Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Jan Krönke, Lars Bullinger, Frank G. Rücker, Verena I. Gaidzik, MD, Michael WM Kühn, Karin Bezet, Veronica Teleanu, Peter Paschka, MD, Daniela Späth, Thomas Kindler, MD, Helmut R. Salih, MD, Jürgen Krauter, MD, Arnold Ganser, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner

Blood (2011) 118 (21): 237.

https://doi.org/10.1182/blood.V118.21.237.237

Published: 2011

Journal Articles

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Blood (2011) 118 (21): 412.

https://doi.org/10.1182/blood.V118.21.412.412

Published: 2011

Journal Articles

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Peter Paschka, MD, Anja Stölzle, Andrea Corbacioglu, PhD, David Nachbaur, MD, Thomas Kindler, MD, Alexander C. Burchardt, MD, Helmut R. Salih, MD, Hans-Günther Mergenthaler, MD, Hans J. Salwender, MD, Daniela Späth, MSc, Lars Bullinger, Juergen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2011) 118 (21): 415.

https://doi.org/10.1182/blood.V118.21.415.415

Published: 2011

Journal Articles

Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications

Blood (2010) 116 (21): 909.

https://doi.org/10.1182/blood.V116.21.909.909

Published: 2010

Journal Articles

Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study

Michela Tassara, eronika Hofer, V, Konstanze Döhner, Marie Lilienfeld-Toal, Gerhard Held, MD, Katharina Götze, Heinz A. Horst, MD, PhD, Sibylla Wilhelm, MD, Stephan Kremers, CA, MD, Elisabeth Koller, Daniela Späth, Silja Mack, Carina Morlok, Martin Göttlicher, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 185.

https://doi.org/10.1182/blood.V116.21.185.185

Published: 2010

Journal Articles

Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG)

Blood (2010) 116 (21): 101.

https://doi.org/10.1182/blood.V116.21.101.101

Published: 2010

Journal Articles

Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup

Thomas Buchner, MD, Richard F. Schlenk, MD, Markus Schaich, MD, Konstanze Döhner, MD, Rainer Krahl, MD, J\)rgen Krauter, MD, Maria Cristina Sauerland, MSc, Daniela Späth, Michael Kramer, Arnold Ganser, MD, Dietger W Niederwieser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD, Hartmut Dohner, MD, Dieter Hoelzer, MD, R\)diger Hehlmann, MD, Verena Hoffmann, MA., Markus Pfirrmann, PhD

Blood (2010) 116 (21): 2175.

https://doi.org/10.1182/blood.V116.21.2175.2175

Published: 2010

Journal Articles

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

Frank G. Rücker, Stephan Stilgenbauer, M.D., Martin Bommer, Daniela Späth, Silja Mack, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 2184.

https://doi.org/10.1182/blood.V116.21.2184.2184

Published: 2010

Journal Articles

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Prof./M.D., Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 1586.

https://doi.org/10.1182/blood.V114.22.1586.1586

Published: 2009

Journal Articles

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Verena I. Gaidzik, M.D., Lars Bullinger, M.D., Andrea Corbacioglu, Ph.D., Manuela Zucknick, Ph.D., Axel Benner, M.Sc., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, M.D., Jürgen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 824.

https://doi.org/10.1182/blood.V114.22.824.824

Published: 2009

Journal Articles

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Lars Bullinger, M.D., Verena I. Gaidzik, M.D., Andrea Corbacioglu, Ph.D., Axel Benner, M.Sc., Manuela Zucknick, Ph.D., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, MD, Juergen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 825.

https://doi.org/10.1182/blood.V114.22.825.825

Published: 2009

Journal Articles

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Konstanze Döhner

Blood (2008) 112 (11): 699.

https://doi.org/10.1182/blood.V112.11.699.699

Published: 2008

Journal Articles

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

Richard F. Schlenk, MD, Konstanze Döhner, MD, Michael Kneba, MD, Francesco del Valle, MD, Frank Hartmann, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Katharina Götze, MD, Jörg Th. Fischer, MD, Marianne Habdank, Daniela Späth, Silja Groner, Andrea Corbacioglu, Axel Benner, MSC, Stefan Fröhling, Hartmut Döhner

Blood (2007) 110 (11): 297.

https://doi.org/10.1182/blood.V110.11.297.297

Published: 2007

Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

Blood (2007) 110 (11): 1837.

https://doi.org/10.1182/blood.V110.11.1837.1837

Published: 2007

Journal Articles

The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.

Sabine Kayser, MD, Konstanze Döhner, MD, Jürgen Krauter, MD, Daniela Späth, Silja Groner, Brigitte Schlegelberger, MD, Gudrun Göhring, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2007) 110 (11): 881.

https://doi.org/10.1182/blood.V110.11.881.881

Published: 2007

Journal Articles

Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.

Richard F. Schlenk, MD, Andrea Corbacioglu, MD, Jürgen Krauter, MD, Lars Bullinger, MD, Michael Morgan, MD, Daniela Späth, MD, Irina Schäfer, MD, Stefan Frohling, MD, Arnold Ganser, MD, Hartmut Dohner, MD, Konstanze Dohner, MD

Blood (2006) 108 (11): 4.

https://doi.org/10.1182/blood.V108.11.4.4

Published: 2006

Journal Articles

Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.

Richard F. Schlenk, MD, Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Juan Du, MD, Daniela Späth, Irina Schäfer, Jürgen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD, for the German-Austrian, AML Study Group (AMLSG)

Blood (2005) 106 (11): 2352.

https://doi.org/10.1182/blood.V106.11.2352.2352

Published: 2005

NARROW

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications

Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study

Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG)

Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.

Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.

Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only